Al Dawaa Medical Services Co.
TTADAWUL:416335.50
SAR
+0.22
(+0.62%)
ISIN
SA15H14I11H6
Return %
Stock
S&P 500
1Y
-47.25
14.20
3Y
-62.43
81.12
5Y
- -
68.34
Capital Structure
SAR
•
in mil. unless spec.Working Capital
SAR
•
in mil. unless spec.Growth Rates
SAR
•
in mil. unless spec.Quarterly Revenue
SAR
•
in mil. unless spec.Quarterly Earnings Per Share
SAR
•
in mil. unless spec.Quarterly Dividends Per Share
SAR
•
in mil. unless spec.Company Description
- CEO
- Mohammad Saad Butti Al-Farraj Al-Subaiai
- Full Time Employees
- 6,359
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Eastern Cement Towers Al Khobar Eastern Province Saudi Arabia 31952
- IPO Date
- Mar 14, 2022
- Website
- al-dawaa.com.sa
- Similar Companies
- Business
- Al-Dawaa Medical Services Company Al-Dawaa Medical Services Company operates as a leading pharmaceutical retail chain in the Kingdom of Saudi Arabia and the Kingdom of Bahrain, offering a comprehensive range of prescription drugs, over-the-counter medications, dietary supplements, perfumes, cosmetics, beauty tools, personal care products, health and wellness items, medical supplies, and equipment through an extensive network of over 900 pharmacies, online platforms, and wholesale channels; it also provides transportation and logistics services, pharmaceutical warehousing, land transport of goods, self-storage management, third-party marketing services, pharmaceutical agency activities, telehealth, homecare, digital pharmacy solutions, primary care, mobile healthcare, genetics and biotechnology services, and manufacturing of single-use medical consumables, examination tables, surgical furniture, mechanical beds, thermometers, respirators, and anesthesia solutions. The company, founded in 1993 and headquartered in Al Khobar, Saudi Arabia, serves retail consumers, wholesale clients, and healthcare providers primarily in the Middle East region through its integrated segments of retail pharmacies, wholesale, logistics, beauty and personal care, and health services, positioning it as the second-largest pharmacy retailer in Saudi Arabia with approximately 21% market share. Recent developments include a strategic manufacturing partnership with Avalon Pharma to localize production of essential medications and enhance pharmaceutical supply security in line with Saudi Vision 2030, a collaboration with EVA Pharma for sustainable access to high-quality medicines in the Saudi market, the establishment of a new limited liability company Modawaa in partnership with Mouwasat Medical Services Company, the opening of a pharmacy in Bahrain in 2024, ongoing expansion with plans for additional stores in 2025, the ramp-up of revenue from its PREMI initiative, and strengthening of its private-label portfolio with over 75 products in development across fast-moving consumer goods and pharmaceuticals.